09:38 AM EST - ProMIS Neurosciences, Inc. : Announced today initiation of a program to construct and test a multivalent peptide vaccine for Alzheimer’s disease. The critical first steps in vaccine development will be carried out by VIDO-InterVac, a global leader in vaccine research and development. ProMIS Neurosciences, Inc.
shares T.PMN are trading unchanged at $0.14.
